SCHEMBL26679987

SCHEMBL26679987

O=c1ccc2c(-c3ccc(CN[SH](=O)=O)cc3)ccnc2[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ENPP1 P22413 3/20 0.38
▸ CHUK O15111 9/20 0.38
▸ IKBKB O14920 9/20 0.38
▸ MAPK8 P45983 2/20 0.36
▸ INSR P06213 1/20 0.36
▸ CAMKK2 Q96RR4 1/20 0.36
▸ PDE3B Q13370 5/20 0.36
▸ PDE3A Q14432 5/20 0.36
▸ ENPP3 O14638 1/20 0.35
▸ ROCK1 Q13464 2/20 0.35
▸ DAPK3 O43293 1/20 0.35
▸ JAK2 O60674 1/20 0.35
▸ PRKD3 O94806 1/20 0.35
▸ MAP4K4 O95819 1/20 0.35
▸ PAK4 O96013 1/20 0.35
▸ CSF1R P07333 1/20 0.35
▸ RET P07949 1/20 0.35
▸ IGF1R P08069 1/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ PRKACA P17612 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26679905 0.85 NUDT1 (0.40) ENPP1CHUKIKBKBMAPK8INSR
SCHEMBL26877422 0.84 ADRB2 (0.41) ENPP1CHUKIKBKBMAPK8INSR
SCHEMBL26679935 0.82 IKBKB (0.46) ENPP1CHUKIKBKBMAPK8INSR
SCHEMBL24600503 0.81 PRKCI (0.43) ENPP1CHUKIKBKBMAPK8INSR
SCHEMBL26679912 0.81 BTK (0.39) ENPP1CHUKIKBKBPDE3BPDE3A
Hydrochloric Acid SCHEMBL26679859 0.81 CDK9 (0.36) ENPP1CDK9
SCHEMBL24600509 0.81 ENPP1 (0.37) ENPP1CHUKIKBKBMAPK8INSR
Hydrochloric Acid SCHEMBL29691541 0.80 PRKCI (0.42) ENPP1CHUKIKBKBMAPK8INSR
SCHEMBL26679934 0.80 IKBKB (0.42) CHUKIKBKBMAPK8INSRCAMKK2
Hydrochloric Acid SCHEMBL26679823 0.80 PRKCI (0.42) ENPP1CHUKIKBKBMAPK8INSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240140944-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF TXINNO BIOSCIENCE INC. (KR) 2024-05-02 — — US claimed
EP-4276100-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF Txinno Bioscience Inc. (KR) 2023-11-15 — — EP claimed
CN-116669726-A Novel naphthyridinone derivatives having inhibitory activity against exonuclease-phosphodiesterase and use thereof 谛希诺生物科技有限公司 2023-08-29 — — CN claimed
US-20240140944-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF TXINNO BIOSCIENCE INC. (KR) 2024-05-02 — — US disclosed
EP-4276100-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF Txinno Bioscience Inc. (KR) 2023-11-15 — — EP disclosed
CN-116669726-A Novel naphthyridinone derivatives having inhibitory activity against exonuclease-phosphodiesterase and use thereof 谛希诺生物科技有限公司 2023-08-29 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240140944-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF ENPP1, ENPP3, ENTPD5 ENPP1 1/4885CHUK 747/4885IKBKB 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback